Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The product will be marketed by Dr. Reddy's Laboratories Inc.
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Subscribe To Our Newsletter & Stay Updated